Measured by the ability of the immobilized protein to block Fibronectin-mediated adhesion of NIH‑3T3 mouse embryonic fibroblast cells. rhTenascin-C immobilized at 15 μg/mL, in the presence of 0.1 μg/mL human Fibronectin, will block approximately 70%-90% NIH3/T3 cell adhesion (5 x 104 cells/well, 100 μL/well).
Source
Mouse myeloma cell line, NS0-derived human Tenascin C protein Gly23-Pro625, with a C-terminal 6-His tag
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.10 EU per 1 μg of the protein by the LAL method.
Applications/Dilutions
Dilutions
Bioactivity
Theoretical MW
65.3 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
SDS-PAGE
97 kDa, reducing conditions
Publications
Read Publications using 3358-TC in the following applications:
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
3 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in PBS.
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute at 500 μg/mL in sterile PBS.
Notes
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Recombinant Human Tenascin C Protein, CF
150-225
Cytotactin
Glioma-associated-extracellular matrix antigen
GMEM
GP 150-225
hexabrachion (tenascin C, cytotactin)
hexabrachion (tenascin)
Hexabrachion
HXB
HXBcytotactin
JI
MGC167029
Myotendinous antigen
neuronectin
Tenascin C
Tenascin J1
tenascin
tenascin-C isoform 14/AD1/16
Tenascin-C
TNC
TN-C
TNGP
Background
Tenascin C, also known as hexabrachion, cytotactin, neuronectin, GMEM, JI, myotendinous antigen, glioma-associated-extracellular matrix antigen, and GP 150-225, is a member of the Tenascin family of extracellular matrix proteins. It is secreted as a disulfide-linked homohexamer whose subunits can vary in size from approximately 200 kDa to over 300 kDa due to differences in glycosylation (1). Rotary-shadowed electron micrographs of the purified molecule show six strands joined to one another at one end in a globular domain with each arm terminating in a knob-like structure (2-3). The human Tenascin C monomer is synthesized as a precursor with a 22 amino acid (aa) signal sequence and a 2179 aa mature chain (SwissProt # P24821). The mature chain consists of a coiled-coil region (aa 118-145), followed by 15 EGF-like domains, 15 fibronectin type-III domains, and a fibrinogen C-terminal domain. In addition, there are 23 potential sites of N-linked glycosylation. Alternative splicing within the fibronectin type-III repeats produces six isoforms for human Tenascin C. Mature human Tenascin C (isoform 1) shares 84% aa sequence identity with mature mouse Tenascin C. In the developing embryo, Tenascin C is expressed during neural, skeletal, and vascular morphogenesis (1, 2). In the adult, it virtually disappears with continued basal expression detectable only in tendon-associated tissues (1, 2). However, greatup-regulation in expression occurs in tissues undergoing remodeling processes seen during wound repair and neovascularization or in pathological states such as inflammation or tumorigenesis (1, 4-5). Biologically, Tenascin C functions as an adhesion-modulatory extracellular matrix protein (1, 4-8). Specifically, it antagonizes the adhesive effects of fibronectin, and impacts the ability of fibroblasts to deposit and contract the matrix by affecting the morphology and signaling pathways of adherent cells (5-7). Tenascin C acts by blocking syndecan-4 binding at the edges of the wound and by suppressing fibronectin-mediated activation of RhoA and focal adhesion kinase (FAK) (4-8). Tenascin C thus promotes epidermal cell migration and proliferation during wound repair.
Hsia, H.C. and J.E. Schwarzbauer (2005) J. Biol. Chem. 280:26641.
Nies, D.E. et al. (1991) J. Biol. Chem. 266:2818.
Erickson, H.P and J.L. Iglesias (1984) Nature 311:267.
Orend, G. et al. (2003) Oncogene 22:3917.
Wenk, M.B. et al. (2000) J. Cell Biol. 150:913.
Midwood, K.S. et al. (2004) Mol. Biol. Cell 15:5670.
Midwood, K.S. and J. E. Schwarzbauer (2002) Mol. Biol. Cell 13:3601.
Hsia, H.C. and J.E. Schwarzbauer (2006) J. Surg. Res. 136:92.
There are no reviews for Tenascin C (3358-TC).
By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
FAQs for Tenascin C (3358-TC). (Showing 1 - 1 of 1 FAQs).
One of our clients is looking for antibodies against tenascin C and fibronectin that could be used for FFPE rat tissues. These antibodies should exclusively recognize tenascin C and fibronectin and do not cross react with each other. Can you inform me if you have these antibodies?
Here is a link to Tenascin C antibodies we have validated in rat tissues for IHC-P Here are antibodies we have validated in fibronectin in rat tissues for IHC-P
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
=
÷
Review this Product
Be the first to review our Recombinant Human Tenascin C Protein, CF and receive a gift card or discount.